No, Jardiance is not a GLP-1 medication. Jardiance (generic name empagliflozin) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, a separate drug class with a different mechanism.
The confusion is understandable. Both classes are prescribed for type 2 diabetes, and both appear often in news coverage about weight and cardiometabolic health. Still, they work in different parts of the body and perform different jobs.
This guide covers what Jardiance is and how it works. It also explains its four FDA-approved uses and why clinicians often prescribe it alongside a GLP-1 medication instead of choosing between them.
What Drug Class Is Jardiance? Understanding SGLT2 Inhibitors
SGLT2 inhibitors act mainly on the kidney. GLP-1 medications act on the pancreas, gut, and brain. Empagliflozin is one of several SGLT2 inhibitors, so it belongs to an established drug family that is separate from GLP-1 therapies.
How Empagliflozin Works in the Kidneys
SGLT2 is the main transporter that pulls filtered glucose back into the bloodstream. Empagliflozin blocks this transporter. As a result:
- The kidney’s threshold for glucose drops.
- More glucose leaves the body in the urine.
- More salt and water are also excreted, which lowers blood volume and reduces the heart’s workload.
This process does not depend on insulin, which is a key conceptual difference from how GLP-1 medications work.
Other Medications in the Same SGLT2 Class
Other SGLT2 inhibitors include dapagliflozin and canagliflozin. Knowing a drug’s class matters clinically: it shapes the side-effect profile, the organs targeted, and how the drug can be combined with other medications.
How SGLT2 Inhibitors Differ From GLP-1 Medications
GLP-1 medications work through hormonal signaling. In general terms, they:
- Stimulate insulin release
- Reduce glucagon secretion
- Slow gastric emptying
- Promote a sense of fullness
SGLT2 inhibitors skip that signaling entirely. They remove excess glucose through the urine. Both classes support better blood sugar control, but they get there through different physiological pathways.
Two Different Mechanisms, Two Different Organ Targets
A simple way to frame the difference:
- Jardiance: glucose excretion through the kidneys
- GLP-1 medications: signaling among the gut, brain, and pancreas
These mechanisms shape how each drug feels day to day. Jardiance may increase urination. GLP-1 medications more often affect appetite and digestion.
What Counts as a “True” GLP-1 Medication
GLP-1 receptor agonists include semaglutide-based therapies, liraglutide, dulaglutide, and exenatide. Tirzepatide is technically a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1. Most consumer content leaves out this distinction.
Jardiance fits none of these categories.
Jardiance’s Four FDA-Approved Indications
Jardiance has expanded well beyond its original diabetes approval. As of 2026, it carries four FDA-approved uses, according to its official prescribing information. Information about these uses is often split across separate diabetes, cardiology, and kidney resources.
Type 2 Diabetes: Glycemic Control
Jardiance’s original use is improving blood sugar control in adults with type 2 diabetes. It lowers A1C by about 1%, a clinically meaningful improvement in blood sugar control. GLP-1 medications also meaningfully improve A1C, though through a different pathway.
Heart Failure: Reducing Hospitalization and Cardiovascular Death
Jardiance is approved for adults with heart failure, whether or not they have diabetes. This benefit ties back to its fluid-reducing effect, since lower blood volume eases strain on the heart. These approvals came in 2021 and 2022.
Chronic Kidney Disease: Slowing Disease Progression
In 2023, Jardiance was approved for adults with chronic kidney disease (CKD), with or without diabetes. In the EMPA-KIDNEY trial, empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% compared with placebo (hazard ratio 0.72). Many consumer sites still describe Jardiance mainly as a “diabetes pill,” so this use is often underreported.
Cardiovascular Risk Reduction in Type 2 Diabetes With Heart Disease
Jardiance also lowers the risk of cardiovascular death in adults with type 2 diabetes and established heart disease. Taken together, these four indications show how Jardiance has grown from a glucose-lowering pill into a therapy that protects the metabolic, cardiac, and renal systems.
Weight Loss: Where the Two Drug Classes Really Diverge
Jardiance can produce modest weight loss, usually around 2% to 3% of starting body weight, or about 4 to 8 pounds in trials. In studies, people taking the 10 mg dose lost about 2.8%, and those taking 25 mg lost about 3.2%.
GLP-1 medications are associated with markedly greater weight reduction. The difference comes from mechanism: Jardiance excretes glucose, while GLP-1 medications reduce appetite and slow digestion. For Jardiance, weight loss is a secondary effect. For GLP-1 medications, weight management is often a central treatment goal.
Comparable Cardiovascular Benefit, Different Clinical Strengths
Research shows that both classes reduce major adverse cardiovascular events (MACE), with no statistically significant difference between them. Their strengths differ in other areas:
- SGLT2 inhibitors offer more pronounced kidney protection and a stronger reduction in heart failure hospitalizations.
- GLP-1 medications show stronger weight-related and broader cardiovascular benefits.
Neither class is “better” overall. Each has a distinct protective profile, which is why guidelines increasingly treat them as complementary.
Why Jardiance and GLP-1 Medications Are Often Prescribed Together
Many patients with type 2 diabetes, heart disease, or kidney disease take both classes. For example, if blood sugar goals are not met on a GLP-1 medication alone, a clinician may add an SGLT2 inhibitor such as Jardiance. The reverse can also happen. This approach addresses different organ systems at the same time.
ADA 2026 Guidance on Combination Therapy
The American Diabetes Association’s 2026 Standards of Care recommend an SGLT2 inhibitor and/or a GLP-1 receptor agonist with demonstrated cardiovascular benefit for people with type 2 diabetes who have established ASCVD, high ASCVD risk, heart failure, or CKD. This recommendation applies regardless of A1C level. It formally supports combination use for high-risk patients, a point most consumer content does not mention.
Comparable A1C Control, Different Pathways
Meta-analysis data shows that both classes meaningfully lower A1C, with no statistically significant difference between them. Because they reach similar results through different mechanisms, combining them can add benefit instead of duplicating it.
Safety and Side-Effect Differences Worth Knowing
Common SGLT2 inhibitor effects:
- Increased urination
- Genital yeast infections
- Volume depletion (fluid loss)
- A rare risk of euglycemic diabetic ketoacidosis
Common GLP-1 medication effects:
- Gastrointestinal symptoms such as nausea and vomiting
SGLT2 inhibitors also carry minimal risk of hypoglycemia (low blood sugar), which matters for some patients. These differences are practical considerations. They do not mean one class is safer overall.
How This Fits Into a Broader Metabolic Health Picture
Jardiance and GLP-1 medications are tools, not complete solutions on their own. Patients managing diabetes alongside heart or kidney risk usually benefit from a coordinated, clinically supervised plan rather than a single prescription viewed in isolation. When more than one medication class is involved, in-person oversight helps track side effects, kidney function, and cardiovascular markers over time.
Frequently Asked Questions
Is empagliflozin the same as a GLP-1 drug?
No. Empagliflozin (Jardiance) is an SGLT2 inhibitor. It does not activate GLP-1 receptors.
Can Jardiance and a GLP-1 medication be taken together?
Yes. Combination use is common and supported by guidelines for patients with diabetes plus cardiovascular, heart failure, or kidney risk. It should be done under clinical supervision.
Does Jardiance cause weight loss like GLP-1 medications do?
Jardiance causes modest weight loss, roughly 2% to 3% of body weight, through glucose excretion. This is a different mechanism from GLP-1 medications and generally produces a smaller effect.
Conclusion: Two Distinct Drug Classes, One Coordinated Strategy
Jardiance is an SGLT2 inhibitor, not a GLP-1 medication. Its four FDA indications cover type 2 diabetes, heart failure, chronic kidney disease, and cardiovascular risk reduction. SGLT2 inhibitors and GLP-1 medications are increasingly viewed as complementary parts of a comprehensive plan. Understanding how each prescription works gives patients a stronger starting point for conversations with their clinician about long-term metabolic, cardiac, and kidney health.
Next Steps: Understanding Your Own Treatment Plan
For people managing diabetes, heart, or kidney risk alongside weight or metabolic concerns, clinical guidance is a sensible next step. Red Mountain has more than 30 years of clinical experience and an in-person model built around helping patients understand how different medications and therapies fit into a long-term metabolic health plan. Questions like this one are exactly the kind of thing Red Mountain’s providers work through with patients during a consult.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
